Competitive Eurostars proposal for identifying biomarkers to bring Rheumatoid Arthritis Treatment to the market
| Reference number | |
| Coordinator | Lipum AB (publ) |
| Funding from Vinnova | SEK 299 900 |
| Project duration | December 2023 - November 2024 |
| Status | Completed |
| Venture | Preparation projects for international application within health |
| Call | Preparation project for international proposal in health and food 2023 |
Important results from the project
The project was successful. The objective was to, together with the Norwegian company Age Labs AS, formulate a project plan as a basis for a proposal for financial support from Eurostars. Our proposal entitled "Identifying proteomic and epigenetic BIOmarkers to bring advanced Rheumatoid Arthritis Diagnostics and Treatment to the market", with a total budget of 1944850 Euro, was granted during December 2024 by Eurostars.
Expected long term effects
The grant from Eurostars brings together Lipum´s promising development with Age Labs´s expertise in epigenetics. This should provide the opportunity to predict which patients can be expected to benefit the most from Lipum´s drug candidate SOL-116. In the first stage for selection of patients and clearer results in clinical trials. Also, it opens the door to precision medicine, where diagnostic test of patient´s biological characteristics enables an individually tailored treatment.
Approach and implementation
The project was entirely focused on preparing a winning proposal to Eurostars. The work was therefore divided into four smaller work packages, the first of which was to develop a project plan. Furthermore, Lipum and Age Labs did a thorough evaluation of both companies´ incentives and business opportunities. This also led to a joint strategy regarding the establishment, management and ownership of expected new IP. Finally, this work was formulated in a successful Eurostar application.